Ionis Pharmaceuticals Inc logo

IONS

Ionis Pharmaceuticals Inc

$43.95

Earnings Summary

Revenue
$141.92Mn
Net Profits
$-65.17Mn
Net Profit Margins
-45.92%

Highlights

Revenue:

Ionis Pharmaceuticals Inc’s revenue jumped 27.16% since last year same period to $141.92Mn in the Q1 2022. On a quarterly growth basis, Ionis Pharmaceuticals Inc has generated -67.75% fall in its revenue since last 3-months.

Net Profits:

Ionis Pharmaceuticals Inc’s net profit jumped 27.49% since last year same period to $-65.17Mn in the Q1 2022. On a quarterly growth basis, Ionis Pharmaceuticals Inc has generated -129.01% fall in its net profits since last 3-months.

Net Profit Margins:

Ionis Pharmaceuticals Inc’s net profit margin jumped 42.98% since last year same period to -45.92% in the Q1 2022. On a quarterly growth basis, Ionis Pharmaceuticals Inc has generated -189.95% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Ionis Pharmaceuticals Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.62
EPS Estimate Current Year
-0.62

Highlights

EPS Estimate Current Quarter:

Ionis Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.62 - a 12.68% jump from last quarter’s estimates.

EPS Estimate Current Year:

Ionis Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.62.

Key Ratios

Key ratios of the Ionis Pharmaceuticals Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.46
Return on Assets (ROA)
-0
Return on Equity (ROE)
-0.05
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Ionis Pharmaceuticals Inc’s earning per share (EPS) jumped 28.13% since last year same period to -0.46 in the Q1 2022. This indicates that the Ionis Pharmaceuticals Inc has generated 28.13% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ionis Pharmaceuticals Inc’s return on assets (ROA) stands at -0.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ionis Pharmaceuticals Inc’s return on equity (ROE) stands at -0.05.

Dividend Per Share (DPS):

Ionis Pharmaceuticals Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-04
-0.71
-0.46
35.21%

Company Information

For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Its scientific innovation began and continues with the knowledge that sick people depend on it, which fuels its vision of becoming one of the most successful biotechnology companies.

Organisation
Ionis Pharmaceuticals Inc
Headquarters
Carlsbad, California, US
Employees
757
Industry
Health Technology
CEO
Brett Monia